fight news
Drug donanemab seen as turning point in dementia fight – BBC
A new drug, donanemab, is being hailed as a turning point in the fight against Alzheimer's, after a global trial confirms it slows cognitive decline.
The antibody medicine helps in the early stages of the disease by clearing a protein that builds up in the brains of people with this type of dementia.
Although not a cure, charities say the results in the journal JAMA mark a new era where Alzheimer's can be treated.
The UK's drugs watchdog has started assessing it for possible NHS use.
The drug works in Alzheimer's disease, not in other types of dementia, such as vascular dementia.
In the trials, it appears to have slowed the pace of the disease by about a third, allowing people to retain more of their day-to-day lives and tasks, such as making meals and enjoying a hobby.
Mike Colley, who is 80, is one of only a few dozen patients in the UK to take part in the global trial. He and his family spoke exclusively with the BBC.
Mike gets an infusion each month at a clinic in London and says he is "one of the luckiest people you'll ever meet".
Mike and his family noticed he was having problems with memory and decision-making, not long before he started on the trial.
His son, Mark, said it was very hard to watch at the beginning: "Seeing him struggle with processing information and solving problems was very hard. But I think the decline is reaching a plateau now."
Mike, who is from Kent, said: "I feel more confident every day."
Donanemab, made by Eli Lilly, works in the same way as lecanemab – developed by companies Eisai and Biogen – which created headlines around the world when it was proven to slow the disease.
Although extremely promising, these drugs are not risk-free treatments.
Brain swelling was a common side-effect in up to a third of patients in the donanemab trial. For most, this resolved without causing symptoms. However, two volunteers, and possibly a third, died as a result of dangerous swelling in the brain.
Another antibody Alzheimer's drug, called aducanumab, was recently rejected by European regulators over safety concerns and a lack of evidence that it was effective enough for patients.
In the donanemab trial, researchers examined 1,736 people aged 60 to 85 with early-stage Alzheimer's.
Half of them received a monthly infusion of the treatment and the other half were given a dummy drug, also known as a placebo, over 18 months.
The findings show:
Amyloid is just one part of the complex picture of Alzheimer's, and it is unclear if the treatment will continue to make more difference over a longer period, experts caution.
The drug's effects may be modest, but the results provide further confirmation that removing amyloid from the brain may change the course of Alzheimer's, and help people affected by this devastating disease if they're treated at the right time, they say.
Prof Giles Hardingham from the UK Dementia Research Institute said: "It is terrific to see these results published in full today.
"We have waited a long time for Alzheimer's treatments, so it's really encouraging to see tangible progress continuing to gather pace in the field."
Dr Susan Kohlhaas, from Alzheimer's Research UK, said: "Today's announcement marks another milestone.
"Thanks to decades of research, the outlook for dementia and its impact on people and society is finally changing, and we're entering a new era where Alzheimer's disease could become treatable."
Speaking to BBC Radio 4's PM programme, former Prime Minister David Cameron said resources should be put towards further research into what he called a "statin for the brain".
"We want a pill that people who have the build-up of these proteins in the brain can take every day or every week in order to clear those proteins out of the brain and therefore reduce your chances of getting a disease that causes dementia," he said.
Asked if the government were prepared to invest where needed to roll out new treatments, Mr Cameron said there was a real incentive to do so: "We're a country of sixty million people, with a million people with dementia, many of them in very expensive residential care settings and so there is a lot of savings to be had from effectively treating people….I'm hopeful that our system can deliver."
Lecanemab costs around $27,500 (£21,000) in the US, where it is licensed.
It is not clear how much donanemab may cost and how long it might take to get approval in the UK, but Alzheimer's experts said having two drugs would help promote competition on price.
The UK's drug's watchdog NICE says it has already started work on its appraisal of donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease.
"Our aim is to produce recommendations on its use in the NHS as close as possible to it receiving its UK licence," said a spokesperson.
Mike Colley turned 80 in April. At his birthday party, he surprised his family by singing My Way in front of 40 guests.
He told BBC News: "That's the confidence I have now. I'd never have done that even 12 months ago."
His son Mark added: "I never thought I would see my dad so full of life again. It was an incredible moment."
Dr Emer MacSweeney, consultant neuroradiologist and medical director at Re:Cognition Health, led the trials of donanemab in the UK.
She said: "This is really significant and one of the biggest breakthroughs."
The Alzheimer's Society said: "This is truly a turning point in the fight against Alzheimer's and science is proving that it is possible to slow down the disease."
Around 720,000 people in the UK might potentially benefit from these emerging new Alzheimer's disease treatments if they're approved for use, but the Alzheimer's Society said the NHS is "simply not ready to deliver them".
Kate Lee, CEO for the charity, said: "Timely, accurate diagnosis is key, and currently only 2% of people in England and Wales receive their diagnosis through the specialist investigations needed to be eligible for these treatments.
"Alongside this, these emerging Alzheimer's disease drugs require regular infusions and monitoring, and the NHS is not yet equipped to do this at scale."
I've got dementia – dementia hasn't got me
Fiona Phillips: How common is early Alzheimer's?
JAMA
Trump charged over bid to overturn 2020 election
Fitch strips US of top credit rating after debt row
The female soldiers defending Ukraine's front line
Why India's rice ban could trigger a global food crisis
Thirsty and exhausted, Texans feel the heatwave
Niger coup: A litmus test for democracy in West Africa
The female soldiers defending Ukraine's front line
The fury in Pakistan sparked by a misogynist minister
Moscow residents shrug off drone attacks on city
The truth about baby-led weaning
'Why I want Russia in and France out'
Trump's support thrives despite his legal woes
How a careless slip killed a physicist
A charming city with a dangerous side
Why critics are loving Barbie's Ken
© 2023 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.
A fight inside Mankato East High School last week Friday is re-igniting the debate over school resource officers in Minnesota. In a video taken in the hallways of the school building, school officials say about 10 students were involved in that brawl. One of the students assaulted was Nashawn William’s son.
“I was upset,” said Williams. “He had a blood clot in his right eye at the bottom and his upper torso was swollen…They could have killed my son stomping him on the floor, like you all saw the video, they could have killed my son.”
The fight comes after Supt. Paul Peterson told families in an email this month that “SROs will not be physically located at MAPS schools but will be available on an ‘on call’ basis to assist school staff.”
Scott Hare, Director of Student Support Services with Mankato Area Public Schools, said police were called in to break up the fight. He added that if an SRO had been in the building, the situation would have looked different.
“Having an officer on site, they’re right there. It’s very fast. It will take a couple of minutes for other officers to arrive through 911,” said Hare. “An SRO can read the situation and make the correct judgment call on the type of support that they would need to bring in.”
A new law prohibits SROs from placing a student in a face-down position and bans certain holds on the head, neck and across most of the torso. Besides Mankato, at least a dozen other law enforcement agencies have pulled their SROs across the state arguing the law would prevent them from doing their job.
RELATED: Minnesota Chiefs of Police Association meets with attorney general over new school resource officer law
“Once you take that presence out of the school, everybody feels like they can run around because they know the teachers can’t do anything,” said Williams.
Elizabeth Hanke is a parent within the school district and believes the state is overreaching by getting involved with placing policies at schools.
“We need more local government and community involvement. We need to give authority and agency back to our teachers and police officers, and still be able to hold them accountable for when they’re not doing their jobs effectively,” said Hanke.
Last month, Attorney General Keith Ellison said what’s written in the law is clear, however, Governor Tim Walz’s office tells 5 EYEWITNESS NEWS Walz remains open to a special session addressing this matter.
Any person with disabilities who needs help accessing the content of the FCC Public File may contact KSTP via our online form or call 651-646-5555
This website is not intended for users located within the European Economic Area.
© KSTP-TV, LLC
A Hubbard Broadcasting Company
KSTP Follow
The last Fight Week prior to the mega Fulton-Inoue/Spence-Crawford showdowns offers up some interesting action.
FRIDAY
Thompson Boxing sadly bids farewell after 23 years of promoting boxing in Southern California. Their final show is headlined by welterweight Louie Lopez (13-2-1, 4 KOs) against an opponent TBA. You can catch the action on YouTube and Facebook.
SATURDAY
ESPN presents former undisputed lightweight champion George “Ferocious” Kambosos Jr. (20-2, 10 KOs) against Maxi Hughes (26-5-2, 5 KOs) in a twelve round IBF world title eliminator from the FireLake Arena in Shawnee, Oklahoma.
UFC Fightpass has exciting junior middleweight KO artist Serhii “El Flaco” Bohachuk (22-1, 22 KOs) against former world title challenger Patrick Allotey (42-4, 32 KOs) at the Chumash Casino Resort in Santa Ynez, California.
ProBox TV has a pro fight card from the Radisson Victoria Plaza in Montevideo, Uruguay, with middleweight Amilcar Vidal Jr (16-1, 12 KOs) rebounding from his first loss against Domicio Rondon (17-5, 11 KOs).
So we have a fighter from Australia against a UK fighter at a venue on Oklahoma. Looks like this one will go the distance!
My thoughts (re the fighters and venue) exactly but why do you think that this means a distance fight?
Am I ridiculous for thinking that Hughes has a chance in this one, Pete?? He’s been on a nice little run as of late against some decent guys including a former world champion, albeit a blown-up featherweight.
I was just thinking the same. Maxi is on a nice run; If you take away the win against a mentally and physically compromised Teo, has George done much?
Getting whitewashed against Haney twice and close wins against Bet and Selby doesn’t make a great resume. I think Maxi is a live dog.
Don’ think so-has five losses and not much KO power. Kambosos pretty average as well but should have enough to beat this guy.
Only time he got f’d up was vs someone who wore Reyes gloves. As long as Kambosos isn’t wearing those, Hughes may not be psyched out. He like kept the Reyes gloves and showed them off about how much he hated the padding and feel to them. It was in a YouTube video.
I think he does have a chance. I always felt the stars aligned perfect for Kambosos when he fought Lopez. Lopez was overconfident and fought a fight that gave Kambosos a chance. Plus he was better at taking Lopez’s power then we thought which I also think caught Lopez off guard. Other then that, like Streetgang said…what else has he really done that separates him from Hughes? I maybe in the minority but I thought Selby beat him.
So yes I think Hughes could outpoint him. I am not sure if that is my pick but it is a reasonable outcome. Just to clarify when I earlier said it would go the distance I was referring to their KO % …that comment had nothing to do with the venue which I do not think will be relevant as to whether it goes the distance or not.
I remember the Selby fight and thinking it was close but Lee may have nicked it.
I will be pulling for Maxi, George has become a bit unbearable for me.
I think I might just take this week off and just save the excitement for next weekend
Session expired
Please log in again. The login page will open in a new tab. After logging in you can close it and return to this page.
The IBF’s 38th Annual Convention will kick off this weekend at The Fairmont Chicago Millennium Park, in Chicago, Illinois from May 28 – June 1, 2023. After 38 years, the organization will be returning to the Midwest to celebrate the IBF’s 40th year. The IBF celebrated its 2nd Annual Convention in Dearborn, Michigan in 1985 and a return to the region is long overdue. “We are excited for this milestone event and are looking forward to gathering with the boxing community in Chicago and the Midwest,” said IBF President Daryl Peoples.
During the convention the IBF hosts several events and seminars. Notably, the IBF also presents annual awards at each convention, and proudly announces its top award recipients for 2022 to be presented at the Awards Banquet closing the organization’s convention festivities on Wednesday, May 31, 2023. The IBF is proud to announce some of it’s top awards for 2022 in anticipation of the upcoming convention.
Jersey Joe Walcott Award
The Jersey Joe Walcott Award, the organization’s highest honor, will go to Naoya Inoue. In spectacular fashion, Inoue unified the Bantamweight division with a second-round knockout win over Nonito Donaire. Naoya won the IBF title in 2019 and defended six times.
Female Fighter of the Year
Receiving the IBF Female Fighter of the Year Award is Chantelle Cameron who unified the Female Jr. Welterweight division. Cameron put on an exciting performance when she beat Undisputed Welterweight Champion Jessica McCaskill by unanimous decision and became the Undisputed Champion in the division.
Fight of the Year
IBF– Sivenathi Nontshinga vs. Hector Flores
Female – Katie Taylor vs. Amada Serrano
Intercontinental – Mark Heffron vs. Lennox Clarke
USBA – Robeisy Ramirez vs. Abraham Nova
Jessica McCaskill and Murodjon Akhmadaliev are recieving Championship Rings for 3 successful title defenses.
“We proudly celebrate the notable achievements and remarkable careers of our champions, and the boxers that participated in IBF title fights. These are very well-deserved distinctions as all these fighters have worked incredibly hard to attain these accomplishments. We look forward to celebrating them,” noted Daryl Peoples.
-
fight news2 weeks ago
10 Facts You Probably Didn't Know About “Fight Club” (1999) – High On Films
-
fight news Canada4 months ago
Fight News 2023: Exciting Matchups
-
fight news3 weeks ago
Movies in North Texas theaters on Sept. 1 and coming soon – The Dallas Morning News
-
fight news3 months ago
Kota Miura vs. Joker Fight Club: Date, start time, TV channel and live … – dazn.com
-
fight news3 months ago
2023 Detroit Lions Name Bracket Tournament: Round 1, Part 3 – Pride Of Detroit
-
fight news Canada3 months ago
Get the Inside Scoop on Canadian Boxing with Fightnews.ca
-
fight news3 months ago
Boxing News, Results, Schedule, Rankings » Fightnews.com™ – Fight News
-
fight news Canada4 months ago
Get the Latest Scoop on Fight News